Glecaprevir and Pibrentasvir

Therapeutic indications

Glecaprevir and Pibrentasvir is indicated for:

Chronic hepatitis C virus infection

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Glecaprevir/pibrentasvir combination is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Glecaprevir and Pibrentasvir is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Severe hepatic impairment

Hepatic failure stage IV

Dabigatran etexilate

Dabigatran

Carbamazepine, phenytoin, phenobarbital, primidone

at least one of
Carbamazepine
Phenytoin
Phenobarbital
Primidone

Rifampicin

Rifampicin

Ethinyloestradiol

17 alpha-Ethinylestradiol

St. John's wort

Hypericum perforatum (St John's Wort)

Atazanavir

Atazanavir

Atorvastatin, simvastatin

at least one of
Atorvastatin
Simvastatin

Strong P-gp and CYP3A inducers

at least one of
Strong potency CYP3A4 inducers
Cytochrome P-450 CYP3A5 strong inducers
P-glycoprotein inducers

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2023: MAVIRET Film-coated tablet
Summary of Product Characteristics (SPC) 2023: MAVIRET Coated granules
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈